IORT TARGIT Boost keyvisual
innovationMADE BY ZEISS
Providing a risk-adapted alternative for breast-conserving treatments. ZEISS IORT Solutions
innovationMADE BY ZEISS

TARGIT Boost Irradiation for Breast Cancer:

High effectiveness through targeted irradiation

Additional irradiation of the tumor bed (boost) is part of the standard of care in breast cancer therapy. In intraoperative radiotherapy with the INTRABEAM® from ZEISS, the boost element of the external beam radiation therapy (EBRT) regime can be replaced and be administered to the target tissue immediately after wide local excision. This boost element of the overall treatment regime is highly accurate as it is applied at the time when the tumor bed is visualised during surgery. More than 14 years of clinical experience on more than 12,000 patients attest to the effectiveness of IORT in the treatment of breast cancer. In two studies on the intraoperative boost with the INTRABEAM® from ZEISS compromising a total 450 patients, the five-year recidivism rate was a low 1.5 to 1.7 percent. These are not selected patients with a low recurrence rate.1,2

Main benefits:

  • Very low local recurrence rate.
  • Low rate of side effects.
  • Very good cosmetic result.
  • Reduction of conventional EBRT treatment visits by around 25%.

The intraoperative boost therapy is tolerated very well by patients. As studies on acute and long-term toxicity following the intraoperative boost (20 Gy) have shown, there are no conspicuities. Doctors and patients also found the cosmetic result following the intraoperative boost with the INTRABEAM® from ZEISS to be very good.3,4


The treatment with the TARGIT Boost method shows an improved treatment outcome and can additionally reduce traditional radiotherapy by 5-8 days.2

Comparison of the breast cancer recurrence rate (Non-randomised). With the INTRABEAM® from ZEISS the recurrence rate is only half of the recurrence rate of conventional radiotherapy.1

This method has over 14 years of clinical experience. Clinical results reveal that the recurrence rate is only approximately 1.7 percent in the first five years after surgery.1

Discover more

Sales Request

Any questions about buying our products?

Price Request

Our Sales Team will contact you shortly.

Schedule your Consultation

Our experts will contact you shortly.

Customer Care

Need assistance with your product?

Related Topics

  • 1 Vaidya, J. S., Baum, M., Tobias, J. S., Wenz, F., Massarut, S., Keshtgar, M., … Joseph, D. (2011). Long-Term Results of Targeted Intraoperative Radiotherapy (Targit) Boost During Breast-Conserving Surgery. International Journal of Radiation Oncology*Biology*Physics, 81(4), 1091–1097.
  • 2 Wenz, F., Welzel, G., Blank, E., Hermann, B., Steil, V., Sütterlin, M., & Kraus-Tiefenbacher, U. (2010). Intraoperative Radiotherapy as a Boost During Breast-Conserving Surgery Using Low-Kilovoltage X-Rays: The First 5 Years of Experience With a Novel Approach. International Journal of Radiation Oncology*Biology*Physics, 77(5), 1309–1314.
  • 3 Kraus-Tiefenbacher, U., Bauer, L., Kehrer, T., Hermann, B., Melchert, F., & Wenz, F. (2006). Intraoperative Radiotherapy (IORT) as a Boost in Patients with Early-Stage Breast Cancer – Acute Toxicity. Oncology Research and Treatment, 29(3), 77–82.
  • 4 Kraus-Tiefenbacher, U., Bauer, L., Scheda, A., Fleckenstein, K., Keller, A., Herskind, C., … Wenz, F. (2006). Long-term toxicity of an intraoperative radiotherapy boost using low energy X-rays during breast-conserving surgery. International Journal of Radiation Oncology*Biology*Physics, 66(2), 377–381.